IMS script growth for the month of January when compared to the average of the previous three months, even when adjusted for the extra week in January, was almost 31%. For the week ending Jan 31 script growth was an impressive 67% when compared to the week ending Jan 3. Figures for week ending Feb 7 will be officially available Feb 14. Unofficially, IMS numbers are often available by Wednesday (today) to a company's sales staff for purposes of determining their sales commissions. You do see how the stock is trading today, right?
They'll publish a Seeking Alpha article stating Marty isn't just going to get clinical trial approval 2014 H1 but the FDA gave him special consideration and fast tracked orphan approval ahead of trials. Oh, and they also approved a label for him that includes 19 indications so he can market immediately.
Citron has contracted with the FDA to handle the press releases.